1. Home
  2. TRIP vs NRIX Comparison

TRIP vs NRIX Comparison

Compare TRIP & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TripAdvisor Inc.

TRIP

TripAdvisor Inc.

HOLD

Current Price

$15.19

Market Cap

1.7B

Sector

Technology

ML Signal

HOLD

Logo Nurix Therapeutics Inc.

NRIX

Nurix Therapeutics Inc.

HOLD

Current Price

$19.02

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TRIP
NRIX
Founded
2000
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Programming Data Processing
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.7B
IPO Year
2011
2020

Fundamental Metrics

Financial Performance
Metric
TRIP
NRIX
Price
$15.19
$19.02
Analyst Decision
Hold
Strong Buy
Analyst Count
10
13
Target Price
$15.88
$26.77
AVG Volume (30 Days)
2.1M
1.9M
Earning Date
11-06-2025
01-27-2026
Dividend Yield
N/A
N/A
EPS Growth
124.53
N/A
EPS
0.59
N/A
Revenue
$1,891,000,000.00
$83,687,000.00
Revenue This Year
$5.18
$58.38
Revenue Next Year
$5.08
N/A
P/E Ratio
$25.90
N/A
Revenue Growth
4.25
48.32
52 Week Low
$10.43
$8.18
52 Week High
$20.16
$22.50

Technical Indicators

Market Signals
Indicator
TRIP
NRIX
Relative Strength Index (RSI) 49.86 64.51
Support Level $14.89 $19.02
Resistance Level $15.73 $22.50
Average True Range (ATR) 0.49 1.20
MACD 0.08 0.01
Stochastic Oscillator 56.02 45.99

Price Performance

Historical Comparison
TRIP
NRIX

About TRIP TripAdvisor Inc.

Tripadvisor is the world's leading travel metasearch company. Its platform offers 1 billion reviews and information on several million accommodations, restaurants, experiences, airlines, and cruises. In 2024, 52% of revenue came from the company's core Brand Tripadvisor segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 46% of sales in 2024, and TheFork, its dining brand, represented 10% of revenue (about 8% of sales were intersegment, which are eliminated from consolidated revenue).

About NRIX Nurix Therapeutics Inc.

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.

Share on Social Networks: